Shergill Medical Ltd 10351121 false 2022-09-01 2023-08-31 2023-08-31 The principal activity of the company is Pharmaceutical services Digita Accounts Production Advanced 6.30.9574.0 true true 10351121 2022-09-01 2023-08-31 10351121 2023-08-31 10351121 bus:OrdinaryShareClass1 2023-08-31 10351121 core:CurrentFinancialInstruments core:WithinOneYear 2023-08-31 10351121 core:FurnitureFittingsToolsEquipment 2023-08-31 10351121 core:OtherPropertyPlantEquipment 2023-08-31 10351121 bus:SmallEntities 2022-09-01 2023-08-31 10351121 bus:AuditExemptWithAccountantsReport 2022-09-01 2023-08-31 10351121 bus:FilletedAccounts 2022-09-01 2023-08-31 10351121 bus:SmallCompaniesRegimeForAccounts 2022-09-01 2023-08-31 10351121 bus:RegisteredOffice 2022-09-01 2023-08-31 10351121 bus:CompanySecretaryDirector1 2022-09-01 2023-08-31 10351121 bus:OrdinaryShareClass1 2022-09-01 2023-08-31 10351121 bus:PrivateLimitedCompanyLtd 2022-09-01 2023-08-31 10351121 core:FurnitureFittings 2022-09-01 2023-08-31 10351121 core:FurnitureFittingsToolsEquipment 2022-09-01 2023-08-31 10351121 core:OfficeEquipment 2022-09-01 2023-08-31 10351121 core:OtherPropertyPlantEquipment 2022-09-01 2023-08-31 10351121 core:PlantMachinery 2022-09-01 2023-08-31 10351121 countries:EnglandWales 2022-09-01 2023-08-31 10351121 2022-08-31 10351121 core:FurnitureFittingsToolsEquipment 2022-08-31 10351121 core:OtherPropertyPlantEquipment 2022-08-31 10351121 2021-09-01 2022-08-31 10351121 2022-08-31 10351121 bus:OrdinaryShareClass1 2022-08-31 10351121 core:CurrentFinancialInstruments core:WithinOneYear 2022-08-31 10351121 core:FurnitureFittingsToolsEquipment 2022-08-31 10351121 core:OtherPropertyPlantEquipment 2022-08-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10351121

Shergill Medical Ltd

Unaudited Filleted Abridged Financial Statements

for the Year Ended 31 August 2023

 

Shergill Medical Ltd

Contents

Company Information

1

Abridged Balance Sheet

2

Notes to the Unaudited Abridged Financial Statements

3 to 6

 

Shergill Medical Ltd

Company Information

Director

Mr Satinder Shergill

Company secretary

Mr Satinder Shergill

Registered office

Middlesex House
130 College Road
Harrow
Middlesex
HA1 1BQ

Accountants

Charles Rippin & Turner
Middlesex House
130 College Road
Harrow
Middlesex
HA1 1BQ

 

Shergill Medical Ltd

(Registration number: 10351121)
Abridged Balance Sheet as at 31 August 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

95,408

79,951

Current assets

 

Cash at bank and in hand

 

29,918

9,245

Creditors: Amounts falling due within one year

(6,771)

-

Net current assets

 

23,147

9,245

Total assets less current liabilities

 

118,555

89,196

Accruals and deferred income

 

(3,465)

(3,300)

Net assets

 

115,090

85,896

Capital and reserves

 

Called up share capital

6

2

2

Retained earnings

115,088

85,894

Shareholders' funds

 

115,090

85,896

For the financial year ending 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 13 March 2024
 

.........................................
Mr Satinder Shergill
Company secretary and director

 

Shergill Medical Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Middlesex House
130 College Road
Harrow
Middlesex
HA1 1BQ

These financial statements were authorised for issue by the director on 13 March 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Shergill Medical Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

20% Reducing balance

Fixtures and fittings

20% Reducing balance

Office equipment

20% Reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Shergill Medical Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2022 - 1).

4

Tangible assets

Furniture, fittings and equipment
 £

Other tangible assets
£

Total
£

Cost or valuation

At 1 September 2022

38,196

63,181

101,377

Additions

11,749

27,560

39,309

Disposals

(8,000)

(12,850)

(20,850)

At 31 August 2023

41,945

77,891

119,836

Depreciation

At 1 September 2022

8,420

13,006

21,426

Charge for the year

8,305

15,547

23,852

Eliminated on disposal

(8,000)

(12,850)

(20,850)

At 31 August 2023

8,725

15,703

24,428

Carrying amount

At 31 August 2023

33,220

62,188

95,408

At 31 August 2022

29,776

50,175

79,951

5

Debtors

Debtors includes £Nil (2022 - £Nil) due after more than one year.

6

Share capital

Allotted, called up and fully paid shares

2023

2022

No.

£

No.

£

Ordinary shares of £1 each

2

2

2

2

       

7

Related party transactions

 

Shergill Medical Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

Director's remuneration

The director's remuneration for the year was as follows:

2023
£

2022
£

Remuneration

9,261

9,504